1.95 (0.35%) 3.35 (0.6%) 3.27 pm | 30 Dec 2005
Broking house, Edelweiss Securities is bullish on Nicholas Piramal India, NPIL. It has reiterated a ‘value buy’ rating on the company....
3.21 pm | 28 Dec 2005
Technical Analyst, Prakash Gaba feels that Nicholas Piramal is good investment buy at Rs 240....
2.58 pm | 28 Dec 2005
VVLN Shastri of Firstcall India Equity Advisor feels that investors should stay invested in Nicholas Piramal....
4.07 pm | 25 Nov 2005
Technical Analyst, Salil Sharma, feels that Nicholas Piramal has resistance at Rs 290-300....
3.52 pm | 25 Nov 2005
Mehraboon Irani of Darashaw & Company feels that Nicholas Piramal is one of the better stock in pharma pack....
2.45 pm | 25 Nov 2005
Broking house, Edelweiss Securities is bullish on Nicholas Piramal, NPIL. It has maintained a ‘value buy’ rating on the company. ...
10.31 am | 25 Nov 2005
Investment advisor, PN Vijay, feels that Nicholas Piramal is a good stock to hold....
10.42 am | 24 Nov 2005
Nicholas Piramal has won a 10-year custom manufacturing order, and it expects a revenue of USD12-15 million per year, from this order....
12.38 pm | 16 Nov 2005
NPIL has just announced that Mr Michael J Fernandes will be joining as Executive Director - Custom Manufacturing Group from 1 December 2005 . This is ...
9.33 pm | 14 Nov 2005
Drug major Nicholas Piramal has begun talks with British pharma giant, GlaxoSmithKline for licensing the Avian Flu drug, Zenamavir, branded Relenza....
2.38 pm | 10 Nov 2005
Technical analyst, Vidur Pendharkar, feels that Nicholas Piramal has a major resistance at Rs 272-285....
2.38 pm | 10 Nov 2005
Surjit Pal of KJMC Financial Services, is of the view that investors should not invest in Nicholas Piramal at current levels....
2.14 pm | 09 Nov 2005
Technical analyst, Sachin Chavan, is of the view that one should exit from Nicholas Piramal....
10.09 am | 07 Nov 2005
Darshan Mehta of Anagram Stock Broking, feels that one should prefer Ranbaxy Labs to Natco Pharma....
4.17 pm | 28 Oct 2005
Broking house, Edelweiss Securities is bullish on Nicholas Piramal, NPIL. It has reiterated a 'value buy' rating on the company. ...
8.38 pm | 27 Oct 2005
Mergers and acquisitions just do not stop for drug maker Nicholas Piramal. The company has acquired UK based Avecia Pharmaceuticals for around 9 milli...
11.07 am | 27 Oct 2005
Nicholas Piramal has acquired UK-based Avecia Pharma for 9.5 million pounds. Avecia Pharma has revenues of 36 million pounds. ...
11.41 am | 21 Oct 2005
Ambareesh Baliga of Karvy Stock Broking feels that one can expect 25-30% return in Nicholas Piramal from current levels....
7.46 pm | 20 Oct 2005
Nicholas Piramal came out with its quarterly results on Thursday. The company's operating income and profit are flat in this quarter due to sale of it...